178 related articles for article (PubMed ID: 8625328)
1. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.
Alati T; Worzalla JF; Shih C; Bewley JR; Lewis S; Moran RG; Grindey GB
Cancer Res; 1996 May; 56(10):2331-5. PubMed ID: 8625328
[TBL] [Abstract][Full Text] [Related]
2. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
[TBL] [Abstract][Full Text] [Related]
3. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
Wedge SR; Laohavinij S; Taylor GA; Boddy A; Calvert AH; Newell DR
Clin Cancer Res; 1995 Dec; 1(12):1479-86. PubMed ID: 9815947
[TBL] [Abstract][Full Text] [Related]
5. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.
Synold TW; Newman EM; Carroll M; Muggia FM; Groshen S; Johnson K; Doroshow JH
Clin Cancer Res; 1998 Oct; 4(10):2349-55. PubMed ID: 9796964
[TBL] [Abstract][Full Text] [Related]
6. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet.
Habeck LL; Chay SH; Pohland RC; Worzalla JF; Shih C; Mendelsohn LG
Cancer Chemother Pharmacol; 1998; 41(3):201-9. PubMed ID: 9443636
[TBL] [Abstract][Full Text] [Related]
7. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
Habeck LL; Leitner TA; Shackelford KA; Gossett LS; Schultz RM; Andis SL; Shih C; Grindey GB; Mendelsohn LG
Cancer Res; 1994 Feb; 54(4):1021-6. PubMed ID: 8313357
[TBL] [Abstract][Full Text] [Related]
8. The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol.
Mendelsohn LG; Gates SB; Habeck LL; Shackelford KA; Worzalla J; Shih C; Grindey GB
Adv Enzyme Regul; 1996; 36():365-81. PubMed ID: 8869756
[TBL] [Abstract][Full Text] [Related]
9. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.
Worzalla JF; Shih C; Schultz RM
Anticancer Res; 1998; 18(5A):3235-9. PubMed ID: 9858888
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F
Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277
[TBL] [Abstract][Full Text] [Related]
11. Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity.
Schmitz JC; Grindey GB; Schultz RM; Priest DG
Biochem Pharmacol; 1994 Jul; 48(2):319-25. PubMed ID: 8053927
[TBL] [Abstract][Full Text] [Related]
12. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
13. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
[TBL] [Abstract][Full Text] [Related]
14. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.
Leamon CP; Reddy JA; Dorton R; Bloomfield A; Emsweller K; Parker N; Westrick E
J Pharmacol Exp Ther; 2008 Dec; 327(3):918-25. PubMed ID: 18791065
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
Zhao R; Gao F; Babani S; Goldman ID
Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.
Reddy JA; Dorton R; Westrick E; Dawson A; Smith T; Xu LC; Vetzel M; Kleindl P; Vlahov IR; Leamon CP
Cancer Res; 2007 May; 67(9):4434-42. PubMed ID: 17483358
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG
J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744
[TBL] [Abstract][Full Text] [Related]
18. Diet modulates the toxicity of cancer chemotherapy in rats.
Branda RF; Chen Z; Brooks EM; Naud SJ; Trainer TD; McCormack JJ
J Lab Clin Med; 2002 Nov; 140(5):358-68. PubMed ID: 12434138
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
